Searched for
BIOCON BIOLOGICS REVENUE
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Biocon shares in focus after Q3 PAT drops 96% YoY, 1.5% additional stake acquisition in subsidiaryBiocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the...
- Biocon arm's growth formula: US rollouts & debt reductionBiocon Biologics planned to introduce six new biosimilar products in the US in the next two years, subject to regulatory approval. They emp...
- Biocon Biologics has comprehensive plan to integrate Viatris business: Shreehas Tambe, Biocon Biologics"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Biologics expects big gains from integration of Viatris business, SII dealBiocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...
- Biocon Q4 Results: Profit declines 4% to Rs 283 crConsolidated revenue from operations in the fourth quarter stood at Rs 2,408.8 crore as against Rs 1,842.1 crore in the year-ago period, it...
- Biocon Q3 Results: Net profit rises 11% YoY to Rs 187 croreThe earnings before interest, tax depreciation and amortisation (EBITDA) rose 25% YoY to Rs 537 crore. The EBITDA margins for the third qua...
- Tata Capital picks up 0.85% stake in Biocon Biologics for $30 millionPost the completion of this transaction, Biocon will hold a 95.25 per cent stake in Biocon Biologics.
- Biocon Biologics eyes $200m, plans IPO in 2 years: Mazumdar-ShawIt looks to build a pipeline of 28 biosimilars across global markets in three phases.
- Biocon elevates M B Chinappa as CFO of biosimilar subsidiaryM B Chinappa, who is going to play an important role in Biocon Biologics’ journey towards becoming a global leader in biologics, has been t...
- True North to acquire 2.4% stake in Biocon BiologicsDeal values Biocon Biologics at $3 billion
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- Biocon reports 64% jump in Q4 net riding on biologicsBiocon reported a 64 per cent jump in its net profit for the quarter ending March 2019.
- Biocon posts 52% rise in net profit in Q2Expansion of its biologics footprint in emerging markets and licensing agreements boosted the revenue further, according to the company’s m...
Load More
